Minerva Neurosciences (NASDAQ: NERV) net income
Minerva Neurosciences reported a net loss of $293.4m for fiscal 2025; in fiscal 2024 it reported a net profit of $1.4m. Earnings per share were −$34.67.
Minerva Neurosciences's best year of the last 10 was fiscal 2020. It reported a loss in 8 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$293.4m | −20,492.7% | — | −$34.67 |
| 2024 | $1.4m | — | — | $0.19 |
| 2023 | −$30.0m | — | — | −$4.61 |
| 2022 | −$32.1m | — | — | −$6.01 |
| 2021 | −$49.9m | −2,671.4% | — | −$1.17 |
| 2020 | $1.9m | — | 4.7% | $0.05 |
| 2019 | −$72.2m | — | — | −$1.85 |
| 2018 | −$50.2m | — | — | — |
| 2017 | −$31.5m | — | — | — |
| 2016 | −$31.0m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Minerva Neurosciences net income compared with its sector
By net income for its latest fiscal year, Minerva Neurosciences ranks 446th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 444th | Syndax Pharmaceuticals | −$285.4m | −165.6% |
| 445th | Madrigal Pharmaceuticals | −$288.3m | −30.1% |
| 446th | Minerva Neurosciences | −$293.4m | — |
| 447th | Vera Therapeutics | −$299.6m | — |
| 448th | Roivant Sciences | −$299.8m | −3,629.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Minerva Neurosciences
- How much did Minerva Neurosciences earn in fiscal 2025?
- Minerva Neurosciences reported a net loss of $293.4m for fiscal 2025. In fiscal 2024 it reported a net profit of $1.4m.
- What are the earnings per share of Minerva Neurosciences?
- They were −$34.67 in fiscal 2025, compared with $0.19 in fiscal 2024.
- What was the most profitable year for Minerva Neurosciences?
- Of its last 10 fiscal years, fiscal 2020, with $1.9m.
- Where does Minerva Neurosciences rank in its sector by net income?
- It ranks 446th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Minerva Neurosciences come from?
- From the annual report (Form 10-K) that Minerva Neurosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Minerva Neurosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Minerva Neurosciences: the Minerva Neurosciences page · annual accounts.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.